All In Biotech

NDA 021278 · Sandoz

Focalin

Dexmethylphenidate Hydrochloride · Oral

Last checked: Nov 20, 2026Latest source record: Oct 13, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2001

Nov 13, 2001

Approved uses

1

Original approval plus efficacy supplements

Registered trials

33

11 Phase 3, 3 recruiting

FAERS reports

2,943

992 serious, 23 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ABUSE, MISUSE, AND ADDICTION Focalin has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including Focalin, can result in overdose and death [see Overdosage ( 10 )] , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing Focalin, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout Focalin treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction [see Warnings and Precautions ( 5.1 ) and Drug Abuse and Dependence ( 9.2 )] . WARNING: ABUSE, MISUSE AND...

What it is approved for

From the label in effect May 30, 2024.

Focalin is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) [see Clinical Studies ( 14 )] . Focalin is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) ( 1 ).

Mechanism: Dexmethylphenidate hydrochloride is a CNS stimulant. The mode of therapeutic action in ADHD is not known.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • FOCALIN · DEXMETHYLPHENIDATE HYDROCHLORIDE 5MG · TABLET, ORAL · Prescription · TE AB
  • FOCALIN · DEXMETHYLPHENIDATE HYDROCHLORIDE 10MG · TABLET, ORAL · Prescription · TE AB
  • FOCALIN · DEXMETHYLPHENIDATE HYDROCHLORIDE 2.5MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Dexmethylphenidate" as an intervention, any sponsor and status, largest first.

All 33 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective565
  • nausea158
  • anxiety151
  • fatigue139
  • off label use129
  • headache126
  • feeling abnormal122
  • disturbance in attention112
  • insomnia111
  • decreased appetite110
  • vomiting109
  • abnormal behaviour104

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200414
200519
200626
200739
200839
200950
201052
201177
201284
201375
201485
2015260
2016301
2017235
2018184
2019217
2020157
2021117
2022176
2023205
2024186
2025187
2026158

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Focalin (Dexmethylphenidate HCl)

2024 spending

$102K

Beneficiaries

225

995 claims

Per beneficiary

$455

$1.24 per unit

View as table
YearSpending
2020$80,710
2021$79,176
2022$82,036
2023$93,337
2024$102,482

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 42 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.